Radiopharma Pipeline & Clinical Momentum: Key Insights from the 5th Targeted Radiopharmaceuticals Summit
Targeted radiopharmaceuticals are rapidly establishing themselves as a key pillar of precision oncology, with continued growth across drug development, clinical activity and regulatory progress.
This slide deck, presented by Isabella Pepe, provides a direct view of the data shared on-site, highlighting key trends, pipeline dynamics, and emerging opportunities across the space.
The slides explores where innovation is concentrating across radioconjugates, radioimmunoconjugates, emerging isotope payloads and target landscapes, while highlighting how clinical and regulatory momentum may shape the next wave of value creation in the field.
What the slides cover:
- Pipeline growth is accelerating: Radioconjugates increased from 443 in June 2025 to 547 in June 2026, while radioimmunoconjugates rose from 139 to 148 over the same period.
- Innovation is concentrated across new payloads and targets: The presentation highlights growth across next-generation payloads including 177-Lutetium, 225-Actinium, 212-Lead, 211-Astatine and 161-Terbium, alongside expanding target activity across PSMA, FAP, HER-2 and SSTR2.
- Clinical translation continues to build: The trial landscape includes 474 radioconjugate trials and 310 radioimmunoconjugate trials, with activity spanning early phase development through Phase 4.
- Key charts and figures presented live at the summit, offering a shareable, data-first view of emerging trends.
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
